TransMedics Q3 2026 Earnings: Revenue Rises 41% as Margins Narrow

TransMedics (NASDAQ: TMDX) reported Q3 2026 revenue of $203.0 million, up 41% from $143.8 million a year earlier, while diluted EPS declined to $0.46 from $0.66. Higher Liver and Heart volume through the National OCS Program, logistics growth, and PAD Aviation lifted revenue, but a heavier service mix, rising operating expenses, interest costs, and taxes limited profit conversion.

Core Financial Results

Reported revenue growth included $9.4 million from PAD Aviation charter services. Excluding that contribution, organic revenue was $193.6 million, representing 34.6% growth and showing that most of the quarterly expansion came from TransMedics’ established operations.

Operating income still increased by 21%, but its slower growth relative to revenue reduced the operating margin. Net income and EPS declined even as operating income rose.

Adjusted net income, a non-GAAP measure, was $18.9 million versus $24.5 million in the prior-year quarter.

Business and Revenue Performance

Service revenue grew considerably faster than product revenue and accounted for approximately 44% of total revenue. Organic service growth remained 42.8% after excluding PAD Aviation, indicating that logistics and other established service operations were already expanding before the new contribution.

Management attributed the overall increase primarily to higher Liver and Heart volume through the National OCS Program, additional logistics revenue, and PAD Aviation’s contribution following the company’s July 2026 strategic investment.

Fast Service Growth Did Not Translate Into EPS Growth

The quarter’s central financial issue was the gap between revenue growth and bottom-line performance. Gross margin slipped to 58.5% because service revenue, which carries a different margin profile, became a larger part of the mix. Reduced scrap, lower inventory adjustments, logistics pricing, less supplemental lift usage, lower ground transportation costs per mission, and better fixed-cost leverage partially offset that pressure.

Operating expenses increased 48% to $90.5 million, outpacing the 41% increase in revenue. Research, development, and clinical trial spending rose to $29.2 million from $15.3 million as TransMedics invested in OCS Kidney, Next-Generation OCS, and ENHANCE programs. Selling, general, and administrative expenses increased to $61.3 million from $46.0 million, while stock-based compensation rose to $12.1 million from $8.7 million.

Below operating income, total other expense widened to $4.0 million from $0.3 million, including interest expense of $7.3 million versus $3.5 million. The company also recorded a $7.0 million income tax provision, compared with a $1.3 million tax benefit a year earlier. These items explain why operating income increased while net income and EPS declined. The drop in adjusted EPS shows that the pressure was not limited to the specified non-GAAP adjustments.

Cash and Balance Sheet

TransMedics ended the quarter with $493.0 million in cash, compared with $488.4 million at the end of 2025. Accounts receivable increased to $114.9 million from $84.3 million, and inventory rose to $58.4 million from $48.9 million as the business expanded.

The balance sheet also showed a significantly larger lease footprint. Finance lease right-of-use assets reached $330.4 million, with a corresponding finance lease liability of $351.5 million. Total liabilities increased to $967.2 million from $595.3 million at year-end, while stockholders’ equity rose to $550.7 million from $473.1 million. Convertible senior notes remained the largest reported debt item at $455.0 million.

2026 Revenue Guidance

TransMedics raised its full-year revenue outlook both before and after the expected PAD Aviation contribution. Excluding PAD, the lower end increased by $13 million and the upper end increased by $3 million, resulting in a narrower range with a higher midpoint.

The guidance assumes continued growth in organ utilization and OCS adoption, together with the expected PAD Aviation contribution.

Management Outlook and Clinical Progress

Management described Q3 as a record quarter for both revenue and case volume, achieved before any contribution from ENHANCE Heart Part B or DENOVO Lung. Several clinical and international initiatives could shape the company’s next phase of growth:

• Enrollment in Part A of the Next-Generation OCS ENHANCE Heart trial was completed, and the FDA approved continued access for another 90 patients.
• The FDA granted investigational device exemption approvals for ENHANCE Heart Part B and the DENOVO Lung trial, including CHOPS as a control arm in both studies.
• TransMedics won its first European transplant logistics tender in Italy and plans to introduce OCS NOP operations in Italy, the Netherlands, and Belgium.
• Management said OCS Kidney remained on track for its first-in-human clinical experience in the second half of 2027.

These programs have not yet contributed commercially to the reported quarter, making regulatory execution, trial timing, and subsequent adoption important future variables.

Recent Insider Transactions

Reported transaction data showed one director purchase and one director sale among recent open-market transactions. The records are presented objectively and do not, by themselves, establish insiders’ views of the company’s valuation or outlook.

Other recent records primarily involved stock awards, a stock gift, and the conversion or exercise of derivative securities rather than open-market purchases or sales.

Risks Investors Need to Watch

• Revenue mix could continue to pressure margins. Service revenue is growing faster than product revenue, and the company identified the higher service mix as the main reason gross margin declined.
• Investment spending may limit operating leverage. Clinical programs, product development, additional employees, headquarters infrastructure, and PAD Aviation increased expenses faster than revenue during the quarter.
• Higher financing and tax costs can weaken EPS conversion. Interest expense and the shift from a tax benefit to a tax provision contributed to lower net income despite higher operating profit.
• Guidance depends on continued OCS adoption and PAD execution. The updated outlook assumes ongoing organ utilization growth and approximately $14 million of PAD Aviation revenue.
• Clinical and regulatory timelines remain important. ENHANCE Heart, DENOVO Lung, CHOPS, and OCS Kidney require additional development or regulatory progress before they can produce the commercial opportunities described by management.

Summary

TransMedics delivered rapid Q3 2026 growth across products and services, supported by higher National OCS Program volume, logistics demand, and an initial PAD Aviation contribution. However, the growing service mix, planned development spending, financing costs, and taxes caused margins and EPS to move in the opposite direction from revenue. The raised 2026 revenue outlook points to continued demand, while future profit conversion, PAD integration, European expansion, and clinical execution remain the main areas to monitor.